Whistleblower Allegations Put Law Firms Under Scrutiny

Whistleblower Allegations Put Law Firms Under Scrutiny

A whistleblower complaint filed with the Securities and Exchange Commission (SEC) alleges that lawyers at Paul Weiss and Reed Smith concealed information that could have derailed a $500 million biotech transaction, according to an article by Maia Spoto of Bloomberg Law. 

The claims arise from Joel Cohen, a screenwriter and former Sofie Biosciences board member, who asserts he and his wife were defrauded of at least $38 million. Cohen contends that Sofie deliberately undervalued assets from an earlier acquisition, reducing his preferred shares, and that this dispute was excluded from disclosures during Sofie’s sale to private equity firm Trilantic North America.

Spoto notes that the SEC complaint accuses Paul Weiss’s Jeffrey Marell and Reed Smith’s Michael Sanders of knowing about Cohen’s threatened litigation but omitting it from required filings. While Paul Weiss and Marell are named only in the whistleblower complaint, Reed Smith, Sofie, and others face lawsuits in California. 

Reed Smith has denied wrongdoing, arguing that Cohen already realized substantial returns and waived claims in merger-related releases. Still, Cohen alleges that Sofie, its executives, outside counsel, and valuation firm Kroll LLC engineered a scheme to minimize his payout.

As Spoto explains, the central question is whether Cohen’s dispute was “material” and therefore required disclosure to Trilantic. Legal experts told Bloomberg Law the case illustrates how disclosure decisions can blur the line between professional judgment and ethical breach. For managing partners, the lesson is clear: overlooking or minimizing potential disputes in deal disclosures can expose both clients and firms to securities liability, with whistleblowers increasingly acting as catalysts for scrutiny.